Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6875872 | ASTRAZENECA LP | Compounds |
May, 2014
(9 years ago) | |
US5900424 | ASTRAZENECA LP | Omeprazole magnesium salt form |
May, 2016
(8 years ago) | |
US7411070 | ASTRAZENECA LP | Form of S-omeprazole |
May, 2018
(5 years ago) | |
US6369085 | ASTRAZENECA LP | Form of S-omeprazole |
May, 2018
(5 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5877192 | ASTRAZENECA LP | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
May, 2014
(9 years ago) | |
US5690960 | ASTRAZENECA LP | Pharmaceutical formulation of omeprazole |
Nov, 2014
(9 years ago) | |
US6875872 (Pediatric) | ASTRAZENECA LP | Compounds |
Nov, 2014
(9 years ago) | |
US5877192 (Pediatric) | ASTRAZENECA LP | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
Nov, 2014
(9 years ago) | |
US5714504 | ASTRAZENECA LP | Compositions |
Feb, 2015
(9 years ago) | |
US5690960 (Pediatric) | ASTRAZENECA LP | Pharmaceutical formulation of omeprazole |
May, 2015
(8 years ago) | |
US5714504 (Pediatric) | ASTRAZENECA LP | Compositions |
Aug, 2015
(8 years ago) | |
US5900424 (Pediatric) | ASTRAZENECA LP | Omeprazole magnesium salt form |
Nov, 2016
(7 years ago) | |
US7411070 (Pediatric) | ASTRAZENECA LP | Form of S-omeprazole |
Nov, 2018
(5 years ago) | |
US6369085 (Pediatric) | ASTRAZENECA LP | Form of S-omeprazole |
Nov, 2018
(5 years ago) | |
US6428810 | ASTRAZENECA LP | Pharmaceutical formulation comprising omeprazole |
Nov, 2019
(4 years ago) | |
US6428810 (Pediatric) | ASTRAZENECA LP | Pharmaceutical formulation comprising omeprazole |
May, 2020
(4 years ago) |
Nexium 24Hr is owned by Astrazeneca Lp.
Nexium 24Hr contains Esomeprazole Magnesium.
Nexium 24Hr has a total of 16 drug patents out of which 16 drug patents have expired.
Expired drug patents of Nexium 24Hr are:
Nexium 24Hr was authorised for market use on 28 March, 2014.
Nexium 24Hr is available in tablet, delayed release;oral dosage forms.
Nexium 24Hr can be used as treatment of frequent heartburn by administering a gastric acid reducer, method of treating frequent heartburn by administering an esomeprazole magnesium trihydrate as claimed, method of treating frequent heartburn by administering an esomeprazole magnesium formulation as claimed.
The generics of Nexium 24Hr are possible to be released after 03 May, 2020.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
RTO(RTO) | Mar 28, 2017 |
Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient
Market Authorisation Date: 28 March, 2014
Treatment: Treatment of frequent heartburn by administering a gastric acid reducer; Method of treating frequent heartburn by administering an esomeprazole magnesium formulation as claimed; Method of treating fre...
Dosage: TABLET, DELAYED RELEASE;ORAL